Michael Dattoli, MD
Radiation Oncology · Sarasota, FLNPI 1235240664
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 94.4% of the total across 192 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 24 manufacturers, the largest accounting for just 19.5% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,028, 3.8 times the $273 reported in 2019.
Across 192 payments — averaging $20.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Dendreon Pharmaceuticals LLC$759
- Johnson & Johnson$516
- Pfizer$433
- Astellas Pharma US Inc$423
- Bayer$312
- Novartis$216
- plus $1K from 18 others
What the payments were for
- Food & beverage$3,67794%
- Education$2206%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Dendreon Pharmaceuticals LLC | 29 | $759 |
| Johnson & Johnson(2 entities) | 37 | $516 |
| Pfizer | 22 | $433 |
| Astellas Pharma US Inc | 17 | $423 |
| Bayer | 13 | $312 |
| Novartis | 9 | $216 |
| Progenics Pharmaceuticals, Inc. | 12 | $189 |
| Isoray, Inc | 8 | $139 |
| Boston Scientific | 6 | $127 |
| AbbVie | 6 | $123 |
| Sun Pharmaceutical Industries Inc. | 4 | $88 |
| Myovant Sciences Inc. | 5 | $83 |
| Sumitomo Pharma America, Inc. | 5 | $80 |
| Amgen | 4 | $73 |
| Teleflex LLC | 3 | $67 |
| Tolmar, Inc. | 3 | $55 |
| Bioprotect Medical, Inc. | 2 | $39 |
| Regeneron Healthcare Solutions, Inc. | 1 | $34 |
| Exact Sciences | 1 | $29 |
| Varian Medical Systems, Inc. | 1 | $28 |
| Foundation Medicine, Inc. | 1 | $27 |
| Bard Peripheral Vascular, Inc. | 1 | $24 |
| Telix Pharmaceuticals | 1 | $20 |
| Palette Life Sciences, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- PROVENGE$146
How this compares
$3,897 in reported general payments places this provider in the 80th percentile of 465 radiation oncology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ErleadaApalutamide | 86 | $1,324,941 |
| XtandiEnzalutamide | 39 | $465,572 |
| Abiraterone Acetate | 49 | $39,548 |
| OrgovyxRelugolix | 13 | $35,209 |
| Cabergoline | 302 | $28,758 |
| Estradiol (Twice Weekly)Estradiol | 186 | $13,560 |
| Dutasteride | 436 | $12,642 |
| MyrbetriqMirabegron | 13 | $11,306 |
| Pentoxifylline | 235 | $10,371 |
| Tamsulosin Hcl | 411 | $8,503 |
| DottiEstradiol | 51 | $5,350 |
| Tadalafil | 67 | $3,954 |
| Finasteride | 183 | $3,426 |
| Bicalutamide | 125 | $2,793 |
| Doxazosin Mesylate | 60 | $1,893 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonErleada | $516 | $1,324,94186 claims |
| Astellas Pharma US IncXtandi, Myrbetriq | $423 | $476,87952 claims |
| Sumitomo Pharma America, Inc.Orgovyx | $80 | $35,20913 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 465 radiation oncology providers in Florida.
Other radiation oncology in Sarasota
- Shravan KandulaOrlando$444K
- Martin KeischMiami Shores$319K
- Marcio FagundesMiami$274K
- Evan ThomasWinter Park$209K
- Rupesh KotechaMiami$208K
- John SylvesterLakewood Ranch$205K
- Ravi ShridharOrlando$192K
- Alan BrownFort Myers$165K
- Akash NandaOrlando$165K
- Michael ChuongMiami$152K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.